



Attachment 2

Attorney Docket SMI-005.01**Certificate of First Class Mailing**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450, on the date set forth below

September 21, 2004 By: Alvin Odidi
Date of Signature and Mail Deposit

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: Isa Odidi and Amina Odidi : Paper No.:
Serial No. 09/168,701 : Group Art Unit: 1617
Filed: October 5, 1998 : Examiner: Webman, Edward J.
For: Controlled Release Pharmaceutical Delivery Device and Process
For Preparation Thereof

DECLARATION UNDER 37 C.F.R. 1.132

Box Fee Amendment
Commissioner for Patents
Washington, DC 20231

Isa Odidi and Amina Odidi declare that:

1. They are co-inventors of and are familiar with the present U.S. Patent Application Serial No. 09/168,701, and they are familiar with the Official Actions Issued in the present application and the reference cited by the Examiner; U.S. Patent No. 4,610,870 to Jain et al.

2. The controlled release pharmaceutical device and the pharmaceutical composition of the present invention comprise, amongst other components, hydroxyethylcellulose (HEC) and hydroxypropylmethyl cellulose (HPMC).

3. In order to demonstrate that hydroxyethylcellulose (HEC) and hydroxypropylcellulose (HPC) are not interchangeable when each are used with

hydroxypropylmethyl cellulose (HPMC), data is provided in Tables 1 and 2 and in Figure 1 for the HPC/HPMC combination compared to the HEC/HPMC combination.


Table 1 Formulation of Model Drug using the Combination of HPC/HPMC vs. HEC/HPMC

<u>Formulation</u>	<u>7.5% HPC and 7.5% HPMC</u>	<u>7.5% HEC and 7.5% HPMC</u>
Model Drug	40%	40%
HPMC	7.5%	7.5%
HPC	7.5%	0%
HEC	0%	7.5%
Lactose	44%	44%
Magnesium Stearate	1%	1%

Table 2 Results from Dissolution studies of the Model Formulations

<u>Time</u>	<u>7.5% HPC and 7.5% HPMC</u>	<u>7.5% HEC and 7.5% HPMC</u>
0	0.00	0.00
1	38.03	28.71
2	56.72	45.27
3	74.81	58.44
4	92.48	69.71
5	100.67	79.9
6	100.97	88.46
7	101.09	95.75
8	101.09	101.33
9	101.39	104.77
10	101.50	104.59
11	101.88	104.71
12	102.10	104.89
13	102.27	105.07
14	102.45	105.18
15	102.51	105.30
16	102.69	105.66
17	102.81	105.68
18	102.87	105.68
19	102.93	105.66
20	102.93	105.66

Figure 1 Dissolution Profiles of Model Formulations



4. The results shown in Table 2 and Figure 1 show significant differences between the release profiles of the two formulations. The amount of drug released in 1 hour is 38% for the HPC/HPMC combination, while the amount of drug released in 1 hour is only 28% for the HEC/HPMC combination. The difference between the two combinations increases with time. For example, the amount of drug released in 4 hours is greater than 80% for the HPC/HPMC combination, while the amount of drug released in 4 hours is less than 70% for the HEC/HPMC combination. Furthermore, it takes 5 hours to release 100% of the drug for the HPC/HPMC combination, while it takes 8 hours before 100% of the drug is released for the HEC/HPMC combination.

5. These results show significant differences in the effect of drug release and availability of the two formulations and clearly indicate that HEC and HPC are not interchangeable when used in combination with HPMC.


6. The differences between the two formulations can impact the decision as to how often a product ought to be taken daily in order to be effective, which also impacts on patient compliance and wellness. These differences also impact adverse effects or safety especially for high potency drugs with low therapeutic indices.

7. Isa Odidi and Amina Odidi further declare that all statements made herein of his/her own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

June 8 2004

June 8 2004

Respectfully submitted,


Isa Odidi


Amina Odidi

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.